Avid Bioservices Inc (CDMO)

[biopharm]

So in Feb 2019 we have some others trying to fight cancer and trying to figure out how to best improve fendiline. Since Omeros and others knowing that there are two brakes on the immune system, we now see just in Aug 2019 that researchers below FOUND a way to battle cancer in a more efficacious way.

Betabodies is Bavituximab 2.0 and it is amazing how patents become new again with a slight change to the targeting of flipped PS, equaling more license fees and royalties to CDMO

___________

Feb 2019

John F Kennedy with Van der Hoeven


...
...

The patent is on both the screening method and the new use for fendiline as an anti-cancer therapeutic. The next step is to improve the drug in ways that make it more efficacious and marketable.

...
...

https://med.uth.edu/news/2019/02/04/patent-protects-new-role-for-old-drug-that-shows-promise-for-fighting-cancer/

_______

Aug 2019

John F Kennedy with Van der Hoeven etc (now with PS Targeting the 2nd brake that Omeros and others are going to require)

Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function

Walaa E Kattan,
Wei Chen,
Xiaoping Ma,
Tien Hung Lan,
Dharini van der Hoeven,
Ransome van der Hoeven,
John F Hancock

Published 26 August 2019

https://www.life-science-alliance.org/content/2/5/e201900431